News
Panelists discuss that, based on EMERALD trial data, elacestrant provides consistent clinical benefit in metastatic breast ...
The frequency was calculated for each autosomal and X chromosome marker using 249 unrelated individuals and 188 unrelated females, respectively. Table 1 summarizes the size range and number of ...
Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer ... (1,185/3,262 alts).
Background: Mutations in PTPN11, encoding tyrosine phosphatase SHP2, are present in 4-6% of AML. Largest report includes 27 patients (pts). Methods: Analysis included AML patients (pts) treated at MD ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results